

Regio- and Stereoselective Ring-Opening Reaction of Spiro-Epoxyoxindoles with Ammonia under Catalyst-Free Conditions

Bangzhi Zhang,^a Yiping Li,^a Guangjun Bao,^a Gongming Zhu,^{a,b} Jing Li,^a Lijuan Wang,^a Bao Zhang,^a Wangsheng Sun,^{*,a} Liang Hong,^{*,b} and Rui Wang^{*,a}

^a School of Life Sciences, Key Laboratory of Preclinical Study for New Drugs of Gansu Province, Lanzhou University, Lanzhou, 730000, P. R. China.

^b School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, P. R. China.

E-mail: sunws@lzu.edu.cn; hongliang@sysu.edu.cn; wangrui@lzu.edu.cn

Contents


1. General information	S2
2. General procedure for preparation of 2	S3
3. Scale-up Experiment	S3
4. Transformations of the Products of 2a'	S3-4
5. Characterization of 2-4	S5-16
6. Copies of HPLC spectra for 2-4	S17-25
7. Copies of NMR spectra for 2-4	S26-61

1. General information

Unless stated otherwise, all reactions were carried out in flame dried glassware. All solvents were purified and dried according to standard methods prior to use. Spiro-Epoxyoxindoles **1** were prepared according to literature.¹ ¹H and ¹³C NMR spectra were recorded on a Varian instrument (300 MHz and 75 MHz, respectively) and internally referenced to tetramethylsilane signal or residual protio solvent signals. Data for ¹H NMR are recorded as follows: chemical shift (δ , ppm), multiplicity (s = singlet, d = doublet, t = triplet, m = multiplet, q = quartet or unresolved, coupling constant(s) in Hz, integration). Data for ¹³C NMR are reported in terms of chemical shift (δ , ppm). IR spectra were recorded on a FT-IR spectrometer and only major peaks were reported in cm⁻¹. Optical rotations were reported as follows: $[\alpha]_{D}^{rt}$ (c: g/100 mL, in solvent). High resolution mass spectra (HRMS) were obtained by the ESI ionization sources. The ee value determination was carried out using chiral HPLC with Daicel Chiracel column on Waters with a 996 UV-detector.


[1] S. Hajra, S. Maity ,R. Maity, *Org. Lett.* **2015**, 17, 3430–3433

2. General procedure for preparation of 2




In an ordinary vial, spiro-epoxyoxindoles **1** (0.10 mmol) was added to MeOH (1.0 mL) in the ammonia atmosphere at room temperature. The mixture was stirred at this temperature for the requisite amount of time as monitored by TLC. The solvent was removed under vacuum and residue was chromatographed on silica gel (DCM:MeOH 20:1) and fractions were collected and concentrated in vacuo to provide the pure desired products **2**.

3. Scale-up Experiment



In an ordinary vial, spiro-epoxyoxindoles **1'** (10.0 mmol) was added to MeOH (60.0 mL) in the ammonia atmosphere at room temperature. The mixture was stirred at this temperature for the requisite amount of time as monitored by TLC. The solvent was removed under vacuum and residue was chromatographed on silica gel (DCM:MeOH 20:1) and fractions were collected and concentrated in vacuo to provide the pure desired products **2a'**.

4. Transformations of the Product of 2a'




(a) To a solution of **2a'** (80 mg, 0.3 mmol) in CH₂Cl₂ (1 mL) was added dry pyridine (48 μL) and CS₂ (14 μL) at 0 °C. After 4h, MeI (15 μL) was added and the mixture stirred at room temperature for 4h. Then the mixture was acidified with 1N HCl and extracted with EtOAc. The combined organic layers were washed with water, brine, dried over Na₂SO₄ and the solvent was removed under vacuum and residue was chromatographed on silica gel (petroleum ether/AcOEt 1:1) and fractions were collected and concentrated in vacuo to provide the pure desired products **3** (68.8 mg, 64% yield).

(b) To a solution of **3** (0.22 mmol) in CH₂Cl₂ (1 mL) was added dry pyridine (35 μL) and MsCl (58 μL) at room temperature for overnight. Then the mixture was neutralized with 1N HCl, and extracted with EtOAc. The combined organic layers were washed with water, brine, dried over Na₂SO₄ and the solvent was removed under vacuum and residue was chromatographed on silica gel and fractions were collected and concentrated in vacuo to provide the pure desired products **4** (38 mg, 51% yield).

5. Characterization of 2-4

3-(aminomethyl)-1-benzyl-3-hydroxyindolin-2-one (2a).



90% yield;

White solid, m.p. 95 – 97 °C;


¹H NMR (300 MHz, CDCl₃) δ 7.46 – 7.14 (m, 7H), 7.05 (t, *J* = 7.3 Hz, 1H), 6.70 (d, *J* = 7.8 Hz, 1H), 4.96 (d, *J* = 15.7 Hz, 1H), 4.78 (d, *J* = 15.7 Hz, 1H), 3.08 (s, 2H), 2.87 (bs, 3H);

¹³C NMR (75 MHz, CDCl₃) δ 178.1, 142.6, 135.4, 129.7, 129.2, 128.8, 127.7, 127.1, 123.8, 123.1, 109.5, 75.0, 48.6, 43.6;

IR: 3370, 1716, 1614, 1468, 1358, 1266, 1177, 1081, 737 cm⁻¹;

HRMS (ESI): C₁₆H₁₆N₂O₂+H, Calc: 269.1285, Found: 269.1289.

3-(aminomethyl)-1-benzyl-4-chloro-3-hydroxyindolin-2-one (2b).



86% yield;

White solid, m.p. 60 – 62 °C;


¹H NMR (300 MHz, DMSO) δ 7.43 – 7.28 (m, 4H), 7.23 (dd, *J* = 16.5, 7.8 Hz, 2H), 7.00 (d, *J* = 8.1 Hz, 1H), 6.74 (d, *J* = 7.8 Hz, 1H), 6.22 (bs, 1H), 4.88 (q, *J* = 16.1 Hz, 2H), 3.35 (bs, 1H), 3.34 (d, *J* = 12.4 Hz, 3H), 3.11 (d, *J* = 12.4 Hz, 1H);

¹³C NMR (75 MHz, DMSO) δ 177.16, 145.28, 135.94, 130.67, 130.18, 128.54, 127.32, 127.15, 126.66, 123.18, 107.91, 77.90, 45.58, 42.63;

IR: 3435, 2252, 1657, 1027, 824, 761 cm⁻¹;

HRMS (ESI): C₁₆H₁₅ClN₂O₂+H, Calc: 303.0895, Found: 303.0900.

3-(aminomethyl)-1-benzyl-5-fluoro-3-hydroxyindolin-2-one (2c).



83% yield;

White solid, m.p. 154 – 156 °C;


¹H NMR (300 MHz, CDCl₃) δ 7.36 – 7.19 (m, 5H), 7.11 (dd, *J* = 7.5, 2.5 Hz, 1H), 6.88 (td, *J* = 8.9, 2.6 Hz, 1H), 6.60 (dd, *J* = 8.6, 4.0 Hz, 1H), 4.93 (d, *J* = 15.8 Hz, 1H), 4.75 (d, *J* = 15.8 Hz, 1H), 3.18 (bs, 3H), 3.05 (q, *J* = 13.3 Hz, 2H);

¹³C NMR (75 MHz, CDCl₃) δ 177.91, 159.40 (d, *J* = 240.75 Hz), 138.31, 135.03, 130.96 (d, *J* = 7.5 Hz), 128.87, 127.78, 127.06, 115.88 (d, *J* = 23.25 Hz), 112.08 (d, *J* = 24.75 Hz), 110.19 (d, *J* = 7.5 Hz), 75.18, 48.40, 43.71;

IR: 3366, 1718, 1491, 1345, 1267, 1174, 1026, 736 cm⁻¹;

HRMS (ESI): C₁₆H₁₅FN₂O₂+H, Calc: 287.1190, Found: 287.1194.

3-(aminomethyl)-1-benzyl-5-chloro-3-hydroxyindolin-2-one (2d).



85% yield;

White solid, m.p. 110 – 112 °C;


¹H NMR (300 MHz, CDCl₃) δ 7.39 – 7.19 (m, 6H), 7.14 (dd, *J* = 8.3, 2.0 Hz, 1H), 6.59 (d, *J* = 8.3 Hz, 1H), 4.91 (d, *J* = 15.8 Hz, 1H), 4.73 (d, *J* = 15.8 Hz, 1H), 3.12 (bs, 3H), 3.06 – 2.90 (m, 2H);

¹³C NMR (75 MHz, CDCl₃) δ 177.73, 140.81, 134.87, 131.25, 129.36, 128.83, 128.47, 127.75, 126.99, 124.31, 110.45, 75.41, 48.50, 43.60;

IR: 3345, 1722, 1484, 1343, 1174, 813, 736 cm⁻¹;

HRMS (ESI): C₁₆H₁₅ClN₂O₂+H, Calc: 303.0895, Found: 303.0896.

3-(aminomethyl)-1-benzyl-5-bromo-3-hydroxyindolin-2-one (2e).



81% yield;

White solid, m.p. 115 – 117 °C;


¹H NMR (300 MHz, DMSO) δ 7.54 (d, *J* = 2.0 Hz, 1H), 7.47 – 7.19 (m, 6H), 6.76 (d, *J* = 8.3 Hz, 1H), 4.87 (q, *J* = 16.0 Hz, 2H), 3.39 (bs, 3H), 3.00 (d, *J* = 12.7 Hz, 1H), 2.89 (d, *J* = 12.7 Hz, 1H);

¹³C NMR (75 MHz, DMSO) δ 177.14, 142.05, 135.97, 133.36, 131.48, 128.60, 127.36, 127.13, 127.00, 114.25, 110.93, 76.49, 48.38, 42.48;

IR: 3436, 1716, 1614, 1468, 1358, 1266, 1177, 1054, 761 cm⁻¹;

HRMS (ESI): C₁₆H₁₅BrN₂O₂+H, Calc: 347.0390, Found: 347.0394.

3-(aminomethyl)-1-benzyl-3-hydroxy-5-methylindolin-2-one (2f).



73% yield;

White solid, m.p. 98 – 101 °C;


¹H NMR (300 MHz, DMSO) δ 7.45 – 7.19 (m, 6H), 7.00 (d, *J* = 7.9 Hz, 1H), 6.68 (d, *J* = 7.9 Hz, 1H), 4.84 (q, *J* = 15.9 Hz, 2H), 3.29 (bs, 3H), 2.91 (q, *J* = 12.9 Hz, 2H), 2.25 (s, 3H);

¹³C NMR (75 MHz, DMSO) δ 177.40, 140.24, 136.39, 131.25, 130.65, 129.04, 128.54, 127.26, 127.14, 124.72, 108.75, 76.07, 48.53, 42.44, 20.70;

IR: 3438, 2250, 1656, 1468, 1358, 1266, 1177, 1055, 761 cm⁻¹;

HRMS (ESI): C₁₇H₁₈N₂O₂+H, Calc: 283.1441, Found: 283.1443.

3-(aminomethyl)-1-benzyl-3-hydroxy-5-methoxyindolin-2-one (2g).



76% yield;

White solid, m.p. 90 – 92 °C;


¹H NMR (300 MHz, CDCl₃) δ 7.35 – 7.15 (m, 5H), 6.97 (d, *J* = 2.4 Hz, 1H), 6.69 (dd, *J* = 8.5, 2.4 Hz, 1H), 6.56 (d, *J* = 8.5 Hz, 1H), 4.91 (d, *J* = 15.7 Hz, 1H), 4.70 (d, *J* = 15.7 Hz, 1H), 3.71 (s, 3H), 3.15 (bs, 3H), 2.99 (s, 2H);

¹³C NMR (75 MHz, CDCl₃) δ 177.80, 156.18, 135.52, 135.41, 130.70, 128.70, 127.53, 127.02, 113.95, 110.76, 109.94, 75.67, 55.64, 48.74, 43.54;

IR: 3368, 1710, 1604, 1494, 1346, 1275, 1179, 1018, 734 cm⁻¹;

HRMS (ESI): C₁₇H₁₈N₂O₃+H, Calc: 299.1390, Found: 299.1394.

3-(aminomethyl)-1-benzyl-6-chloro-3-hydroxyindolin-2-one (2h).



89% yield;

White solid, m.p. 79 – 81 °C;


¹H NMR (300 MHz, CDCl₃) δ 7.38 – 7.17 (m, 6H), 7.01 (dd, *J* = 7.9, 1.6 Hz, 1H), 6.68 (d, *J* = 1.6 Hz, 1H), 4.92 (d, *J* = 15.8 Hz, 1H), 4.71 (d, *J* = 15.8 Hz, 1H), 3.02 (q, *J* = 13.1 Hz, 2H), 3.01 (bs, 3H);

¹³C NMR (75 MHz, CDCl₃) δ 178.08, 143.76, 135.36, 134.83, 128.92, 127.85, 127.74, 127.01, 124.78, 122.99, 110.04, 74.84, 48.43, 43.63;

IR: 3340, 1726, 1611, 1490, 1374, 1265, 1178, 1075, 738 cm⁻¹;

HRMS (ESI): C₁₆H₁₅ClN₂O₂+H, Calc: 303.0895, Found: 303.0894.

3-(aminomethyl)-1-benzyl-6-bromo-3-hydroxyindolin-2-one (2i).



83% yield;

White solid, m.p. 99 – 101 °C;


¹H NMR (300 MHz, CDCl₃) δ 7.42 – 7.04 (m, 7H), 6.83 (s, 1H), 4.91 (d, *J* = 15.8 Hz, 1H), 4.70 (d, *J* = 15.8 Hz, 1H), 2.98 (d, *J* = 13.7 Hz, 2H), 2.88 (bs, 3H);

¹³C NMR (75 MHz, CDCl₃) δ 177.96, 143.90, 134.83, 128.95, 128.26, 127.88, 127.02, 125.98, 125.15, 123.30, 112.78, 74.84, 48.36, 43.64;

IR: 3361, 1720, 1605, 1486, 1430, 1353, 1176, 1117, 1061, 734 cm⁻¹;

HRMS (ESI): C₁₆H₁₅BrN₂O₂+H, Calc: 347.0390, Found: 347.0389.

3-(aminomethyl)-1-benzyl-7-chloro-3-hydroxyindolin-2-one (2j).



78% yield;

White solid, m.p. 83 -85 °C;


¹H NMR (300 MHz, CDCl₃) δ 7.35 – 7.12 (m, 7H), 6.99 (t, *J* = 7.8 Hz, 1H), 5.28 (s, 2H), 3.05 (d, *J* = 13.2 Hz, 2H), 3.02 (bs, 3H);

¹³C NMR (75 MHz, CDCl₃) δ 178.73, 138.60, 137.08, 132.32, 132.17, 128.57, 127.18, 126.29, 124.13, 122.43, 115.72, 74.39, 48.69, 44.59;

IR: 3332, 1721, 1608, 1452, 1353, 1267, 1134, 735 cm⁻¹;

HRMS (ESI): C₁₆H₁₅ClN₂O₂+H, Calc: 303.0895, Found: 303.0894.

3-(aminomethyl)-1-benzyl-3-hydroxy-7-methylindolin-2-one (2k).



75% yield;

White solid, m.p. 82 – 84 °C;


¹H NMR (300 MHz, CDCl₃) δ 7.35 – 7.18 (m, 4H), 7.14 (d, *J* = 7.0 Hz, 2H), 6.96 (d, *J* = 4.6 Hz, 2H), 5.16 (d, *J* = 16.9 Hz, 1H), 5.06 (d, *J* = 16.9 Hz, 1H), 3.03 (s, 5H), 2.21 (s, 3H);

¹³C NMR (75 MHz, CDCl₃) δ 179.14, 140.43, 137.17, 133.53, 130.14, 128.81, 127.15, 125.50, 123.22, 121.66, 120.17, 74.44, 48.94, 44.71, 18.62;

IR: 3365, 1714, 1452, 1354, 1163, 733 cm⁻¹;

HRMS (ESI): C₁₇H₁₈N₂O₂+H, Calc: 283.1441, Found: 283.1443.

3-(aminomethyl)-3-hydroxyindolin-2-one (2l).



80% yield;

White solid, m.p. 214 – 216 °C;


¹H NMR (300 MHz, DMSO) δ 10.37 (bs, 1H), 7.35 (d, *J* = 7.3 Hz, 1H), 7.23 (dd, *J* = 13.5, 5.8 Hz, 1H), 6.98 (t, *J* = 7.4 Hz, 1H), 6.81 (dd, *J* = 14.2, 7.6 Hz, 1H), 3.39 (bs, 3H), 2.92 (q, *J* = 13.2 Hz, 2H);

¹³C NMR (75 MHz, DMSO) δ 178.24, 141.91, 130.29, 129.45, 124.37, 121.75, 109.82, 74.12, 46.61;

IR: 3432, 2251, 1656, 1027, 737 cm⁻¹;

HRMS (ESI): C₉H₁₀N₂O₂+H, Calc: 179.0815, Found: 179.0815.

1-acetyl-3-(aminomethyl)-3-hydroxyindolin-2-one (2m).



2m

88% yield;

White solid, m.p. 136 – 138 °C;


¹H NMR (300 MHz, CDCl₃) δ 9.80 (bs, 1H), 7.88 (d, *J* = 7.9 Hz, 1H), 7.37 (t, *J* = 7.4 Hz, 2H), 7.13 (t, *J* = 7.5 Hz, 1H), 6.59 (bs, 1H), 6.30 (d, *J* = 24.3 Hz, 1H), 3.22 (d, *J* = 5.8 Hz, 1H), 2.93 (d, *J* = 5.8 Hz, 1H), 2.19 (s, 3H);

¹³C NMR (75 MHz, CDCl₃) δ 173.21, 168.85, 136.78, 129.51, 127.17, 126.72, 124.53, 124.25, 57.49, 54.15, 24.39;

IR: 3275, 1668, 1522, 1451, 1299, 927, 735 cm⁻¹;

HRMS (ESI): C₁₁H₁₂N₂O₃+ Na, Calc: 243.0740, Found: 243.0745.

3-(aminomethyl)-3-hydroxy-1-methylindolin-2-one (2n).



2n

87% yield;

White solid, m.p. 68 – 71 °C;


¹H NMR (300 MHz, CDCl₃) δ 7.42 – 7.23 (m, 2H), 7.07 (t, *J* = 7.5 Hz, 1H), 6.82 (d, *J* = 7.7 Hz, 1H), 3.15 (s, 3H), 3.15 (bs, 3H), 3.04 – 2.86 (m, 2H);

¹³C NMR (75 MHz, CDCl₃) δ 177.87, 143.28, 129.65, 129.36, 123.65, 123.05, 108.38, 75.12, 48.36, 26.06;

IR: 2929, 1722, 1614, 1470, 1375, 1249, 1121, 839 cm⁻¹;

HRMS (ESI): C₁₁H₁₂N₂O₃+H, Calc: 193.0972, Found: 193.0973.

1-allyl-3-(aminomethyl)-3-hydroxyindolin-2-one (2o).



85% yield;

White solid, m.p. 62– 64°C;


¹H NMR (300 MHz, CDCl₃) δ 7.35 (d, *J* = 7.2 Hz, 1H), 7.28 (t, *J* = 7.7 Hz, 1H), 7.07 (t, *J* = 7.4 Hz, 1H), 6.81 (d, *J* = 7.8 Hz, 1H), 5.80 (ddd, *J* = 22.1, 10.2, 5.1 Hz, 1H), 5.22 (d, *J* = 7.2 Hz, 1H), 5.18 (s, 1H), 4.34 (dd, *J* = 16.4, 4.9 Hz, 1H), 4.20 (dd, *J* = 16.4, 5.0 Hz, 1H), 3.24 (s, 3H), 2.96 (s, 2H);

¹³C NMR (75 MHz, CDCl₃) δ 177.65, 142.41, 130.98, 129.51, 129.35, 123.71, 123.00, 117.58, 109.26, 75.12, 48.48, 42.07;

IR: 3360, 1715, 1613, 1468, 1364, 1184, 1106, 929, 755 cm⁻¹;

HRMS (ESI): C₁₂H₁₄N₂O₂+H, Calc: 219.1128, Found: 219.1132.

3-(aminomethyl)-3-hydroxy-1-(4-methoxybenzyl)indolin-2-one (2p).



89% yield;

White solid, m.p. 66 – 68°C;


¹H NMR (300 MHz, CDCl₃) δ 7.34 (d, *J* = 7.3 Hz, 1H), 7.18 (dd, *J* = 9.5, 4.7 Hz, 3H), 7.02 (t, *J* = 7.4 Hz, 1H), 6.81 (d, *J* = 8.4 Hz, 2H), 6.71 (d, *J* = 7.8 Hz, 1H), 4.86 (d, *J* = 15.4 Hz, 1H), 4.69 (d, *J* = 15.5 Hz, 1H), 3.74 (d, *J* = 4.6 Hz, 3H), 3.24 (bs, 3H), 3.01 (s, 2H);

¹³C NMR (75 MHz, CDCl₃) δ 178.00, 158.93, 142.39, 129.52, 129.37, 128.45, 127.36, 123.72, 123.02, 114.08, 109.44, 75.25, 55.14, 48.53, 42.97;

IR: 3357, 1716, 1613, 1513, 1356, 1248, 1178, 1109, 1032, 751 cm⁻¹;

HRMS (ESI): C₁₇H₁₈N₂O₃+H, Calc: 299.1390, Found: 299.1394.

(R)-3-(aminomethyl)-1-benzyl-3-hydroxyindolin-2-one (2a').




91% yield;

$[\alpha]_{\text{D}}^{\text{rt}} = -46^{\circ}$ (c = 1.00, CHCl₃);

HPLC: DAICEL CHIRALCEL OD, Hexane/EtOH = 7/3, flow rate = 1.0 ml/min, retention time:

$t_{\text{major}} = 8.9$, $t_{\text{minor}} = 6.1$, 99% ee.

(R)-3-(aminomethyl)-1-benzyl-3-hydroxy-5-methylindolin-2-one (2f').




75% yield;

$[\alpha]_{\text{D}}^{\text{rt}} = -37^{\circ}$ (c = 1.00, CHCl₃);

HPLC: DAICEL CHIRALCEL OD, Hexane/EtOH = 7/3, flow rate = 1.0 ml/min, retention time:

$t_{\text{major}} = 9.7$, $t_{\text{minor}} = 5.7$, 97% ee.

(R)-3-(aminomethyl)-1-benzyl-3-hydroxy-5-methoxyindolin-2-one (2g').




74% yield;

$[\alpha]_{\text{D}}^{\text{rt}} = -106^{\circ}$ (c = 1.00, CHCl₃);

HPLC: DAICEL CHIRALCEL OD, Hexane/EtOH = 7/3, flow rate = 1.0 ml/min, retention time:

$t_{\text{major}} = 12.1$, $t_{\text{minor}} = 7.1$, 99% ee.

(R)-3-(aminomethyl)-1-benzyl-6-chloro-3-hydroxyindolin-2-one (2h')




88% yield;

$[\alpha]_{\text{D}}^{\text{rt}} = -22^\circ$ (c = 1.00, CHCl₃);

HPLC: DAICEL CHIRALCEL OD, Hexane/EtOH = 7/3, flow rate = 1.0 ml/min, retention time:

$t_{\text{major}} = 8.6$, $t_{\text{minor}} = 6.5$, 98% ee.

(R)-3-(aminomethyl)-1-benzyl-6-bromo-3-hydroxyindolin-2-one (2i')




84% yield;

$[\alpha]_{\text{D}}^{\text{rt}} = -32^\circ$ (c = 1.00, CHCl₃);

HPLC: DAICEL CHIRALCEL OD, Hexane/EtOH = 7/3, flow rate = 1.0 ml/min, retention time:

$t_{\text{major}} = 8.9$, $t_{\text{minor}} = 6.7$, 96% ee.

(R)-3-(aminomethyl)-1-benzyl-7-chloro-3-hydroxyindolin-2-one (2j')




78% yield;

$[\alpha]_{\text{D}}^{\text{rt}} = -49^\circ$ (c = 1.00, CHCl₃).

HPLC: DAICEL CHIRALCEL OD, Hexane/EtOH = 7/3, flow rate = 1.0 ml/min, retention time:

$t_{\text{major}} = 10.4$, $t_{\text{minor}} = 6.3$, 96% ee.

(R)-3-(aminomethyl)-3-hydroxy-1-(4-methoxybenzyl)indolin-2-one (2p').




86% yield;

$[\alpha]_{\text{D}}^{\text{rt}} = -51^{\circ}$ (c = 1.00, CHCl₃).

HPLC: DAICEL CHIRALCEL OD, Hexane/EtOH = 7/3, flow rate = 1.0 ml/min, retention time:

$t_{\text{major}} = 9.9$, $t_{\text{minor}} = 7.1$, 98% ee.

methyl (R)-((1-benzyl-3-hydroxy-2-oxoindolin-3-yl)methyl)carbamodithioate (3).



64% yield;

White solid, m.p. 67 – 68 °C;

¹H NMR (300 MHz, CDCl₃) δ 8.30 (bs, 1H), 7.42 (d, *J* = 7.3 Hz, 1H), 7.36 – 7.16 (m, 6H), 7.05 (t, *J* = 7.5 Hz, 1H), 6.70 (d, *J* = 7.8 Hz, 1H), 4.87 (d, *J* = 15.8 Hz, 1H), 4.82 (bs, 1H), 4.71 (d, *J* = 15.7 Hz, 1H), 4.54 (dd, *J* = 14.3, 6.2 Hz, 1H), 3.96 (dd, *J* = 14.3, 4.0 Hz, 1H), 2.59 (s, 3H);

¹³C NMR (75 MHz, CDCl₃) δ 200.96, 176.72, 141.70, 134.72, 130.20, 128.84, 128.15, 127.77, 127.08, 124.20, 123.68, 109.91, 74.68, 52.45, 43.84, 18.22;


IR: 3454, 1716, 1614, 1358, 1260, 1177, 1005, 730 cm⁻¹;

HRMS (ESI): C₁₈H₁₈N₂O₂S₂+H, Calc: 359.0882, Found: 359.0889.

HPLC: DAICEL CHIRALCEL AS, Hexane/EtOH = 8/2, flow rate = 1.0 ml/min, retention time:

$t_{\text{major}} = 17.9$, $t_{\text{minor}} = 13.6$, 98% ee.

(R)-1-benzyl-2'-(methylthio)-4'H-spiro[indoline-3,5'-thiazol]-2-one (4).



51% yield;

White solid, m.p. 43 – 45 °C;

¹H NMR (300 MHz, CDCl₃) δ 7.46 – 7.24 (m, 6H), 7.20 (td, *J* = 7.8, 1.2 Hz, 1H), 7.06 (td, *J* = 7.6, 0.8 Hz, 1H), 6.73 (d, *J* = 7.8 Hz, 1H), 4.92 (d, *J* = 1.7 Hz, 2H), 4.71 (d, *J* = 15.1 Hz, 1H), 4.52 (d, *J* = 15.1 Hz, 1H), 2.63 (s, 3H);

¹³C NMR (75 MHz, CDCl₃) δ 176.02, 164.03, 141.35, 135.15, 130.66, 129.54, 128.85, 127.82, 127.28, 124.11, 123.60, 109.46, 74.97, 64.23, 44.32, 15.66;

IR: 3378, 1745, 1614, 1490, 1358, 1249, 1177, 1081, 737 cm⁻¹;

HRMS (ESI): C₁₈H₁₆N₂OS₂+H, Calc: 341.0777, Found: 341.0785;


[α]_D^{rt} = - 72°(c = 1.00, CHCl₃);

HPLC: DAICEL CHIRALCEL AD, Hexane/EtOH = 8/2, flow rate = 1.0 ml/min, retention time:


*t*_{major} = 17.8, *t*_{minor} = 21.2, 96% ee.

6. Copies of HPLC spectra for 2-4


(*R*)-3-(aminomethyl)-1-benzyl-3-hydroxyindolin-2-one (Table 3, entry 1)



Chiralpak OD-H column, hexane/EtOH (7:3), flow rate 1.0 mL/min




	Retention time	Area	% Area	Height	Integral type
1	6.024	7715904	50.48	181448	bv
2	8.830	7569897	49.52	148061	vb




	Retention time	Area	% Area	Height	Integral type
1	8.879	14943171	100.00	286775	bb


(*R*)-3-(aminomethyl)-1-benzyl-3-hydroxy-5-methylindolin-2-one (Table 3, entry 2)



Chiralpak OD-H column, hexane/EtOH (7:3), flow rate 1.0 mL/min




	Retention time	Area	% Area	Height	Integral type
1	5.837	5436947	52.86	140415	bb
2	9.993	4848747	47.14	96976	bb




	Retention time	Area	% Area	Height	Integral type
1	5.672	196249	1.75	8806	bb
2	9.693	10989674	98.25	266698	bb


(R)-3-(aminomethyl)-1-benzyl-3-hydroxy-5-methoxyindolin-2-one (Table 3, entry 3)



Chiralpak OD-H column, hexane/EtOH (7:3), flow rate 1.0 mL/min




	Retention time	Area	% Area	Height	Integral type
1	6.869	15830031	50.11	517196	bb
2	12.313	15762766	49.89	288453	bb




	Retention time	Area	% Area	Height	Integral type
1	7.051	161632	0.60	6631	bb
2	12.129	26612364	99.40	451971	bb


(*R*)-3-(aminomethyl)-1-benzyl-6-chloro-3-hydroxyindolin-2-one (Table 3, entry 4)



Chiralpak OD-H column, hexane/EtOH (7:3), flow rate 1.0 mL/min




	Retention time	Area	% Area	Height	Integral type
1	6.195	44617719	49.29	1230356	bv
2	8.402	45906199	50.71	1007696	vb




	Retention time	Area	% Area	Height	Integral type
1	6.537	183726	0.94	5635	bb
2	8.624	19461183	99.06	374773	bb


(*R*)-3-(aminomethyl)-1-benzyl-6-bromo-3-hydroxyindolin-2-one (Table 3, entry 5)



Chiralpak OD-H column, hexane/EtOH (7:3), flow rate 1.0 mL/min




	Retention time	Area	% Area	Height	Integral type
1	6.603	44677878	50.56	1670989	bb
2	8.831	43680220	49.44	1281028	bb




	Retention time	Area	% Area	Height	Integral type
1	6.679	121785	2.20	4540	bb
2	8.924	5416442	97.80	128652	bb


(*R*)-3-(aminomethyl)-1-benzyl-7-chloro-3-hydroxyindolin-2-one (Table 3, entry 6)



Chiralpak OD-H column, hexane/EtOH (7:3), flow rate 1.0 mL/min




	Retention time	Area	% Area	Height	Integral type
1	6.358	13111383	49.38	608499	bb
2	10.518	13441431	50.62	345053	bb




	Retention time	Area	% Area	Height	Integral type
1	6.336	513935	2.03	25822	bb
2	10.443	24788016	97.97	653245	bb

(*R*)-3-(aminomethyl)-3-hydroxy-1-(4-methoxybenzyl)indolin-2-one (Table 3, entry 7)




2p'

Chiralpak OD-H column, hexane/EtOH (7:3), flow rate 1.0 mL/min




	Retention time	Area	% Area	Height	Integral type
1	6.825	46648109	50.59	1301998	bv
2	9.651	45556671	49.41	945292	vb




	Retention time	Area	% Area	Height	Integral type
1	7.117	250256	1.07	6021	bb
2	9.926	23116760	98.93	395584	bb


(*R*)-methyl ((1-benzyl-3-hydroxy-2-oxoindolin-3-yl)methyl)carbamodithioate (Scheme 2, **3**)



Chiralpak AS column, hexane/EtOH (8:2), flow rate 1.0 mL/min




	Retention time	Area	% Area	Height	Integral type
1	13.841	60668556	50.80	1353628	bb
2	18.333	58752826	49.20	556557	bb




	Retention time	Area	% Area	Height	Integral type
1	13.583	657222	1.06	18508	bb
2	17.866	61222987	98.94	587755	bb

(R)-1-benzyl-2'-(methylthio)-4'H-spiro[indoline-3,5'-thiazol]-2-one (Scheme 2, 4)




4


Chiralpak AD column, hexane/EtOH (8:2), flow rate 1.0 mL/min




	Retention time	Area	% Area	Height	Integral type
1	17.858	35387474	50.32	787462	bb
2	21.161	34941844	49.68	708519	bb





	Retention time	Area	% Area	Height	Integral type
1	17.842	16509374	97.94	353649	bb
2	21.160	347475	2.06	9335	bb






2a



























3.390
3.372
3.360
3.167
3.025
2.982
2.913
2.870
2.505
2.500
2.495

4.946
4.893
4.841
4.788

7.544
7.537
7.417
7.410
7.389
7.382
7.357
7.333
7.311
7.285
7.273
7.266
7.257
7.245
6.772
6.744











3.454
3.389
3.285
3.229
3.200
3.187
2.966
2.923
2.897
2.854
2.506
2.500
2.494
2.252


4.915
4.862
4.817
4.764

7.358
7.352
7.327
7.305
7.279
7.265
7.258
7.249
7.236
7.206
7.016
6.990
6.689
6.662















2g



























2I


3.533
3.523
3.509
3.492
3.451
3.429
3.411
3.373
3.325
3.291
3.273
3.256
3.227
2.973
2.929
2.906
2.862
2.492


7.363
7.339
7.261
7.236
7.211
7.196
7.003
6.979
6.954
6.848
6.822
6.800







2k































3





3

